Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered
Human content, AI powered search.

Latest Stories

Search

Human content, AI powered search.

Search Results for obesity

long working hours health risks
Obesity & Weight Management

Long working hours may be fueling the obesity crisis, scientists warn

The study found that a 1 per cent reduction in annual working hours could lead to 0.16 per cent fall in obesity rates

Obesity drugs emerge as pharma’s highest value area
News

Obesity drugs emerge as pharma’s highest value area

GLP-1 medications now drive 38 percent of projected pharma revenue, but concentration raises risk concerns

Novo Nordisk to highlight Wegovy’s clinical data at obesity meet
Obesity & Weight Management

Novo Nordisk to highlight Wegovy’s clinical data at obesity meet

The presentation will be on weight loss drug Wegovy, women with obesity and the next generation weight loss treatments

weight loss drug
Obesity & Weight Management

Semaglutide 7.2mg single-dose pen cleared for adult obesity

The 7.2mg dosage of the drug is given through one injection

weight loss therapies obesity prevention study
Obesity & Weight Management

Weight-loss therapies shouldn’t shift focus from obesity prevention: Study

The study emphasises on utilising therapies and prevention hand-in-hand

Fake obesity drugs thrives as demand soars: Lancet
Obesity & Weight Management

Fake obesity drugs thrives as demand soars: Lancet

Public health experts warn of a "significant and growing threat" as counterfeit injectables like Ozempic and Mounjaro flood the global market

Chris Whitty warns against relying too much on weight loss drugs to fight England's obesity
News

Chris Whitty warns against relying too much on weight loss drugs to fight England's obesity

England's chief medical officer said the better course of action would be to make food healthier and curb obesity

Novo Nordisk
Obesity & Weight Management

Novo Nordisk sues Hims over weight-loss drug patent violation

The lawsuit highlights the friction between obesity drugmakers and companies selling copies using the same active ingredients